臨床研究等提出・公開システム

A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients with Schizophrenia in Japan

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients with Schizophrenia in Japan

Yabuuchi Kazuki

Sumitomo Pharma Co., Ltd.

6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan

cr@sumitomo-pharma.co.jp

Product information center

Sumitomo Pharma Co., Ltd.

6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan

+81-120-034-389

cc@sumitomo-pharma.co.jp

Complete

May. 09, 2022

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Must be fully informed of and understand the objectives, procedures, and possible benefits and risks of the study, and give written informed consent prior to performing any study related activities.
2. Male or female between 18 to 65 years of age (inclusive) at the time of consent.
3. Must meet DSM-5 criteria for schizophrenia as established by clinical interview at Screening.
4. Must have a PANSS total score >= 60 at Screening and Baseline.
5. Must have a CGI-S score >= 3 at Screening and Baseline
6. Judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Baseline and has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
7. In the opinion of the Investigator, subjects must be generally healthy based on Screening medical history, physical examination, vital signs, ECG, and clinical laboratory values (hematology, chemistry, and urinalysis).

1. Have a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder or substance (other than nicotine or caffeine) use disorder within past 12 months or for a total of >= 10 years during the subject's lifetime, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment.
2. At significant risk of harming self, others, or objects based on Investigator's judgment.
3. Have any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
4. Female subjects who are pregnant or lactating.
5. Have any clinically significant abnormal laboratory value(s) at Screening (hematology, chemistry, and urinalysis) as determined by the Investigator.

Both

Schizophrenia

Flexible dose (50 and 75 mg/day) of SEP-363856

The incidence of overall adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

+81-3-5433-3343

Feb. 16, 2022

No

none